The LCD will provide coverage for the Decipher Prostate Biopsy genomic test for men with both favorable and unfavorable intermediate-risk prostate cancer.
Investigators compared expression in different men across the genes from three commercial panels, arguing that the findings highlight important unknowns.
Data from an ongoing study suggests that the drug, combined with an androgen receptor signaling inhibitor, may be efficacious in a particularly hard to treat form of prostate cancer.
The test will be used to identify which metastatic, castration-resistant prostate cancer patients harbor germline BRCA mutations and will likely benefit from Lynparza.
A modified analogue of rucaparib is being used to track PARP-1 expression in PARP inhibitor-treated patients with pancreatic, breast, prostate, and other cancer types.
